Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Galantamine ER Open Label Rapid Dose Escalation Trial in Alzheimer's Disease

Authors not listed

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 2004

Abstract

The purpose of this study is to evaluate the safety and tolerability of an extended release formulation of the drug galantamine using a rapid dose escalation regimen.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-10-26 MST

Cite this

APA
Anonymous. (2004). Galantamine ER Open Label Rapid Dose Escalation Trial in Alzheimer's Disease. <em>Johnson & Johnson Pharmaceutical Research & Development, L.L.C.</em>. https://clinicaltrials.gov/study/NCT00082602
Vancouver
Anonymous. Galantamine ER Open Label Rapid Dose Escalation Trial in Alzheimer's Disease. Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. 2004.
BibTeX
@misc{anon2004Galant, title = {Galantamine ER Open Label Rapid Dose Escalation Trial in Alzheimer's Disease}, author = {Anonymous}, journal = {Johnson & Johnson Pharmaceutical Research & Development, L.L.C.}, year = {2004}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings